Pramipexole-induced psychosis in Parkinson's disease

Psychiatry and Clinical Neurosciences

Volumn 62, Issue 2, 2008, Pages 245-

  Li, Cheng Ta ^a   Tsai, Shih Jen ^a,b   Hwang, Jen Ping ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; PRAMIPEXOLE; QUETIAPINE; SELEGILINE;

AGED; BEHAVIOR DISORDER; BRADYKINESIA; CASE REPORT; DELUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; OLFACTORY HALLUCINATION; PARKINSON DISEASE; PRESCRIPTION; PSYCHOSIS; TREMOR; VISUAL HALLUCINATION;

AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DRUG THERAPY, COMBINATION; HUMANS; MALE; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 42149130972     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2008.01766.x     Document Type: Letter

References (3)

1. Dooley M, Markham A. Pramipexole: A review of its use in the management of early and advanced Parkinson's disease. Drugs Aging 1998 12 : 495 514.
2. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: A meta-analysis. Drug Saf. 2003 26 : 439 444.
3. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur. J. Pharmacol. 1997 324 : 31 37.